Email this article Long-term trastuzumab biotherapy of a breast cancer patient
- Authors: Volodina L.N1, Kulikov E.P2, Grigoryev A.V1, Bublokova M.P1, Zhuravleva O.P1, Chernova V.V1, Kolobaeva R.E1, Sashina E.L1, Sonina L.A1, Mertsalov S.A.2, Mirchetich A.S1, Vinogradov I.Y.1, Kholchev M.Y.1
-
Affiliations:
- Ryazansky Regional Clinical Oncology Dispensary
- I.P. Pavlov Ryazansky State Medical University
- Issue: Vol 20, No 5 (2015)
- Pages: 31-33
- Section: Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/40206
- DOI: https://doi.org/10.17816/onco40206
- ID: 40206
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
L. N Volodina
Ryazansky Regional Clinical Oncology Dispensary390011, Ryazan, Russian Federation
E. P Kulikov
I.P. Pavlov Ryazansky State Medical University390026, Ryazan, Russian Federation
A. V Grigoryev
Ryazansky Regional Clinical Oncology Dispensary390011, Ryazan, Russian Federation
M. P Bublokova
Ryazansky Regional Clinical Oncology Dispensary390011, Ryazan, Russian Federation
O. P Zhuravleva
Ryazansky Regional Clinical Oncology Dispensary390011, Ryazan, Russian Federation
V. V Chernova
Ryazansky Regional Clinical Oncology Dispensary390011, Ryazan, Russian Federation
R. E Kolobaeva
Ryazansky Regional Clinical Oncology Dispensary390011, Ryazan, Russian Federation
E. L Sashina
Ryazansky Regional Clinical Oncology Dispensary390011, Ryazan, Russian Federation
L. A Sonina
Ryazansky Regional Clinical Oncology Dispensary390011, Ryazan, Russian Federation
Sergey A. Mertsalov
I.P. Pavlov Ryazansky State Medical University
Email: mrst16rzn@yandex.ru
MD, PhD 390026, Ryazan, Russian Federation
A. S Mirchetich
Ryazansky Regional Clinical Oncology Dispensary390011, Ryazan, Russian Federation
I. Yu Vinogradov
Ryazansky Regional Clinical Oncology Dispensary390011, Ryazan, Russian Federation
M. Yu Kholchev
Ryazansky Regional Clinical Oncology Dispensary390011, Ryazan, Russian Federation
References
- Семиглазов В.Ф., Семиглазов В.В., Палтуев Р.М. Биологическое обоснование планирования лечения рака молочной железы. Врач. 2012; 11: 2-4.
- Белохвостова А.С., Смирнова И.А., Енилеева А.А. Таргетная терапия в лечении HER2-позитивного рака молочной железы. Сибирский онкологический журнал. 2013; 2 (56): 84-8.
- Minckwitz G. Trastuzumab beyond progression in epidermal growth factor receptor 2-positive advanced breast cancer a German breast croup 26/ breast international group 03-05 study. J. Clin. Oncol. 2009; 27: 1999-2006.
- Rueckert S., Ruehl I., Kahlert S. et al. A monoclonal antibody as an effective therapeutic agent in breast cancer. Trastuzumab. Biol. Ther. 2005; 5 (6): 853-66.
- Фролова М.А. Наиболее значимые итоги 2012 года в лечении рака молочной железы. Практическая онкология. 2013; 14 (1): 51-8.
- Baselga J., Cortes J., Kim S.B. et al. Pertuzumab plus Trastuzumab plus Docetaxel for metastatic breast cancer. N. Engl. J. Med. 2012; 366 (2): 109-19.
